Dato-DXd安全性分析：治疗相关不良事件比较

According to Table 2, the pooled incidence of different safety events is described. From an absolute numerical perspective, Dato-DXd has lower rates of treatment-related adverse events (TRAEs), grade 3 or higher TRAEs, TRAEs leading to death, and serious adverse events (SAEs) compared to SKB264 and SG. However, the rate of TRAEs leading to discontinuation is slightly higher for Dato-DXd. Specifically, Dato-DXd shows a lower incidence of grade 3 or higher hematologic toxicities compared to SG and SKB264. Among non-hematologic toxicities, the incidence of grade 3 or higher stomatitis is slightly lower in Dato-DXd compared to SKB264, and the incidence of grade 3 or higher diarrhea is lower in Dato-DXd compared to SG. However, the incidence of grade 3 or higher nausea and vomiting is slightly higher in Dato-DXd compared to SKB264 or SG.